NCT04914195 - Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer | Biotech Hunter

Enrollment

155

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

September 29, 2022

Study Completion Date

September 29, 2022

Conditions

Advanced Prostate Adenocarcinoma

Interventions

DRUG

Leuprolide Acetate 3.75 MG/ML

Leuprolide Acetate/ Leuprorelin is a depot injection administered as a subcutaneous injection once every month.

Trial Locations (2)

MV hospital and Research Center, Lucknow

Government Med ical College & Superspeciality Hospital Nagpur, Nagpur